Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News iSpecimen Inc ISPC

Technology Software - Application
iSpecimen Inc. is a technology-driven company. The Company's iSpecimen Marketplace platform is designed to transform the biospecimen procurement process to accelerate medical discovery. The Company's technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia... see more

Recent & Breaking News (NDAQ:ISPC)

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

Newsfile December 20, 2024

iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers

Newsfile December 13, 2024

iSpecimen Appoints Robert Lim as CEO and Director

Newsfile December 12, 2024

iSpecimen Named Top Competitor in $4.4 Billion USD Market

Newsfile November 8, 2024

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

GlobeNewswire November 7, 2024

iSpecimen Reports Third Quarter 2024 Results

GlobeNewswire November 7, 2024

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 31, 2024

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 30, 2024

iSpecimen Secures $1 Million Loan; Appoints Three New Board Members

GlobeNewswire September 26, 2024

iSpecimen Announces 1-for-20 Reverse Stock Split

GlobeNewswire September 11, 2024

iSpecimen Reports Second Quarter 2024 Results

GlobeNewswire August 6, 2024

iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

GlobeNewswire July 25, 2024

iSpecimen Reports First Quarter 2024 Results

GlobeNewswire May 7, 2024

iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire April 25, 2024

iSpecimen Reports Full Year 2023 Results

GlobeNewswire March 14, 2024

iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call

GlobeNewswire March 12, 2024

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024

GlobeNewswire March 5, 2024

iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research

GlobeNewswire January 23, 2024

iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024

GlobeNewswire January 18, 2024

iSpecimen Strengthens Global Oncology Biospecimen Offering

GlobeNewswire December 7, 2023